2022 (8 POSTS)
Jensen IS, Wu E, Cyr PL , Claussen M, Winkler T, Salahuddin K, Prats J, et al. 2022. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention patients: A US hospital perspective. Am J Cardiovasc Drugs 22(1):93-104; doi: 10.1007/s40256-021-00491-9 .
View Abstract
Publication: Manuscripts
Alexander AW, Jensen IJ, Hathaway J, Srivastava K, Cyr PL , Sidonio RF, Batt K. 2022. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. J Manag Care Spec Pharm 28(5):518-527; doi: 10.18553/jmcp.2022.21197 .
Publication: Manuscripts
Sacks NC , Healey BE, Raza S, Cyr PL , Boerner G, Sheshadri A. 2022. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv 6(5):1566–1576; doi: 10.1182/bloodadvances.2021004364 .
View Abstract
Publication: Manuscripts
Sheshadri A, Sacks NC , Healey B, Cyr P , Boerner G, Huang HJ. 2022. The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States. J Med Econ 25(1):650–659; doi: 10.1080/13696998.2022.2071065 .
View Abstract
Publication: Manuscripts
Sheshadri A, Sacks NC , Healey BE, Raza S, Boerner G, Huang HJ. 2022. Lung function monitoring after lung transplantation and allogeneic hematopoietic stem cell transplantation. Clin Ther 44(5):755–765.
View Abstract
Publication: Manuscripts
2021 (11 POSTS)
Feuerstadt P, Boules M, Stong L, Dahdal DN, Sacks NC , Lang K, Nelson WW. 2021. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis. SAGE Open Med 9:2050312120986733.
View Abstract
Publication: Manuscripts
Sacks NC , Healey BE, Cyr PL , Slocomb T, James E, Beggs AH, Graham RJ. 2021. Costs and health resource use in patients with X-linked myotubular myopathy: insights from U.S. commercial claims. J Manag Care Spec Pharm 27(8):1019–1026; doi: 10.18553/jmcp.2021.20501 .
View Abstract
Publication: Manuscripts
Dougherty C, Friedman BW, Aurora S, Bariahtaris S, Shrewsbury S, Baker-Wagner M, Sacks N , Kautz S, Cyr P . Impact of INP104 on healthcare resource use among patients in STOP 301. Presentation at American Academy of Neurology Annual Meeting, Virtual, April 2021.
Publication: Abstracts and Presentations
Dougherty C, Friedman BW, Aurora S, Bariahtaris S, Shrewsbury S, Baker-Wagner M, Sacks N , Kautz S, Cyr P . INP104 reduces self-reported ED and urgent care in patients with episodic migraine. Presentation at Academy of Managed Care Pharmacy (AMCP) Annual Meeting, Virtual, April 2021.
Publication: Abstracts and Presentations
Sheshadri A, Sacks NC , Healey B, Raza S, Cyr P , Boerner G, Huang HJ. A descriptive analysis of costs and healthcare resource use in patients with bronchiolitis obliterans syndrome (BOS) following lung transplantation. Poster presentation, ISPOR 25th Annual International Meeting, May 2021.
Publication: Abstracts and Presentations
Wallace E, Sacks NC , Cyr P , Baker-Wagner M. An observational cohort analysis on the economic impact of chronic kidney disease in patients with fabry disease. Poster presentation, ISPOR Annual International Meeting, Virtual, May 2021.
Publication: Abstracts and Presentations
Sacks NC , Healey B, Cyr PL , Slocomb T, James E, Beggs A, Graham RJ. Healthcare resource use and expenditures in patients with x-linked myotubular myopathy (XLMTM). Poster presentation, ISPOR 25th Annual International Meeting, Orlando, FL, April 2021.
Publication: Abstracts and Presentations
Panattoni L, Hernandez J, Liu Y, Sacks NC , Higham R, Stephenson B, Armstrong A. Initial treatment patterns for newly diagnosed, commercially insured patients with psoriasis. Poster presentation, ISPOR, April 2021.
Publication: Abstracts and Presentations
Dean R, Jensen IS, Cyr PL , Miller B, Maru B, Sproule DM, Feltner DE, et al. 2021. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Pol 9(1):1889841; doi: 10.1080/20016689.2021.1889841 .
Publication: Manuscripts
Chew D, Sacks NC , Emden MR, Preib MT, Cyr PL , Wood D, Pokorney SD. 2021. Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States. Am Heart J 233(March):132–140; doi: 10.1016/j.ahj.2020.12.012 .
View Abstract
Publication: Manuscripts
Sheshadri A, Healey B, Sacks N , Wu E, Cyr P , Boerner G, Huang H. 2021. Bronchiolitis obliterans syndrome following lung transplantation: Economic burden by chronic lung allograft dysfunction (CLAD) stage. J Heart Lung Trans 40(4-Sup):S70; doi: 10.1016/j.healun.2021.01.1913 .
View Abstract
Publication: Abstracts and Presentations
2020 (4 POSTS)
Sacks NC , Healey B, Cyr PL , Batt K, Henig NR. The economic burden of bronchiolitis obliterans syndrome (BOS) in allogenic hematopoietic stem cell transplant (alloHSCT) patients with Medicare coverage. Poster presentation, ISPOR 25th Annual International Meeting, Orlando, FL, May 2020.
Publication: Abstracts and Presentations
Dean R, Arjunji R, Awano H, Igarash A, Tanaka A, Jensen IS, Cyr PL et al. Cost-effectiveness of onasemnogene abeparvocec (ZOLGENSMA) for spinal muscular atrophy type 1 against nusinersen in Japan. ISPOR 25th Annual International Meeting, Orlando FL, 2020.
Publication: Abstracts and Presentations
Jensen IS, Hathway J, Cyr PL , Gauden D, Gardiner P. 2020. Cost–consequence analysis of 18 F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362 .
View Abstract
Publication: Manuscripts
Sacks NC , Cyr PL , Preib MT, Everson K, Wood DR, Raza S, Pokorney SD. 2020. Healthcare resource use and expenditures in patients newly diagnosed with paroxysmal supraventricular tachycardia. Am J Cardiol 125(2):215–221; doi: 10.1016/j.amjcard.2019.10.015 .
View Abstract